
|Articles|October 1, 2003
HELIX BIOMEDIX PEPTIDE STUDIED
Helix BioMedix completed a preliminary study designed to evaluate the efficacy of one the company's proprietary peptides, HB64, in reducing severity of mild to moderate acne symptoms.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Shows Durable Skin Clearance in Phase 3 Psoriasis Extension
2
The Emerging Role of Oral Peptide Therapeutics in Psoriasis and Beyond
3
Social Media Mythbusters: Hydrocolloid Pimple Patches
4
Allergan Aesthetics Refreshes APP Loyalty Program for Aesthetic Practices
5










